Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 2, 2002 - Issue 3
Submit an article Journal homepage
28
Views
2
CrossRef citations to date
0
Altmetric
Review

Pharmacoeconomics in oncology

Rebecca B Arbuckle Rebecca B Arbuckle, MS, RPh, Director, Department of Pharmacoeconomics, Division of Pharmacy, Box 706, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA. [email protected]
,
Andrea T Adamus Andrea T Adamus, MS, RPh, Research Specialist, Department of Pharmacoeconomics, Division of Pharmacy, Box 706, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA. [email protected]
&
Krista M King Krista M King, PharmD, BCOP, Research Specialist, Department of Pharmacoeconomics, Division of Pharmacy, Box 706, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA. [email protected]
Pages 251-260 | Published online: 09 Jan 2014

References

  • Shah ND, Vermeulen LC, Santell JP, Hunkler RJ, Hontz K. Projecting Future Drug Expenditures - 2002. Am. j Health-Syst. Pharm. 59,131-142 (2002).
  • Relman AS. Assessment and accountability: the third revolution in medical care. N Engl. jIkld 319,1220–1222 (1988).
  • Donabedian A. Evaluating the quality of medical care. Milbank Q. 44(Suppl.), 166–206 (1966).
  • ••Seminal article on medical outcomes andthe need to include the structure of the medical care system and process of care as outcomes.
  • Bootman JL, Townsend RJ, McGhan WE Introduction to pharmacoeconomics. In: Principles of pharmacoeconomics (2nd Edition). Harvey Whitney Books Company, Cincinnati, OH, USA 5–18 (1996).
  • •Basic starting point for those new to pharmacoeconomics.
  • Barrajon E, de las Penas R. Randomized double-blind crossover study comparing ondansetron, granisetron and tropisetron. A cost-benefit analysis. Support Care Cancer 8,323–333 (2000).
  • •Example of cost-minimization analysis.
  • Johannesson M, Weinstein MC. Designing and conducting cost-benefit analysis. In: Quality of life and pharmacoeconomics in clinical trials (2nd Edition). Spilker B (Ed.), Lippincott Williams & Wilkins, Philadelphia, PA, USA 1085–1092 (1996).
  • Dranitsaris G, Peung P, Ciotti R et al. A multinational study to measure the value that patients with cancer place on improved emesis control following cisplatin chemotherapy. PharmacoEconomics 19(9) 955–967 (2001).
  • •Example of cost-benefit analysis using the willingness-to-pay method.
  • Drummond MF et al. Cost-benefit analysis. In: Methods for the evaluation of healthcare programmes (2nd edition). Drummond MF et al., Oxford University Press, Oxford, UK (1997).
  • ••Excellent resource for pharmacoeconomicmethods used in studies.
  • Lister-Sharp D, McDonagh MS, Khan KS, Kleijnen J. A rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced breast and ovarian cancer. Health TechnoL Assess. 4(17), 1–113 (2000).
  • •Example of cost-effectiveness analysis.
  • Leung PP, Tannock IF, Oza AM, Puodziunas A, Dranitsaris G. Cost-utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast cancer. Clin. OncoL 17,3082–3090 (1999).
  • •Example of cost-utility analysis using time trade-off method.
  • Health Econ. Issue 8 (1999).
  • Health Econ. Issue 6 (1997).
  • Grieve AR Issues for statisticians in pharmaco-economic evaluations. Stat. Med. 17,1715–1723 (1998).
  • O'Brien BJ, Drummond ME Statistical versus quantitative significance in the socioeconomic evaluation of medicines. PharmacoEconomics 5(5), 389–398 (1994).
  • Devicki DA. Relationship of pharmacoeconomics and health-related quality of life. In: Quality of life and pharmacoeconomics in clinical trials (2nd edition). Spilker B (Ed.), Lippincott Williams & Wilkins, Philadelphia, PA, USA 1077–1084 (1996).
  • ••Excellent resource for pharmacoeconomicand quality of life methods.
  • Cramer JA, Spilker B. Quality of life and pharmacoeconomics: an introduction. Lippincott-Raven, Philadelphia, PA, USA 1–48 (1998).
  • •Good resource for quality of life instruments.
  • Hjelmgren J, Berggren F, Andersson E Health-economic guidelines-similarities, differences and some implications. Value Health 4(3), 225–250 (2001).
  • •• Excellent review and comparison of currently available pharmacoeconomic guidelines.
  • Lee SJ, Earle CC, Weeks JC. Outcomes research in oncology: history, conceptual framework and trends in the literature. Natl Cancer Inst. 92 (3), 195–204 (2000).
  • ••Excellent review of outcomes research inoncology that includes a nice conceptual framework and excellent background material.
  • Nuijten M, Meester L, Waibel F, Wait S. Cost effectiveness of letrozole in the treatment of advanced breast cancer in postmenopausal women in the UK. PharmacoEconomics 16(4), 379–397 (1999).
  • Brown RE, Hutton J. Cost-utility model comparing docetaxel and paclitaxel in advanced breast cancer patients. Anti Cancer
  • Messori A, Trippoli S, Becagil P, Tendi E. Treatments for newly diagnosed advanced ovarian cancer: analysis of survival data and cost-effectiveness evaluation. Anti Cancer Drugs 9,491–502 (1998).
  • Cagnoni PJ, Walsh TJ, Prendergast MM et al. Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. j Clin. OncoL 18, 2476–2483 (2000).
  • Rose PG, Lappas PT. Analysis of the cost effectiveness of concurrent cisplatin-based chemoradiation in cervical cancer: implications from five randomized trials. GynecoL Oncol 78,3–6 (2000).
  • Beard SM, Lorigan PC, Sampson FC. The cost-effectiveness of high dose chemotherapy in the treatment of relapsed Hodgkin's disease and non-Hodgkin's lymphoma. Br. j Cancer 82 (1), 81–84 (2000).
  • Longo CJ. Choices of methodology in pharmacoeconomic studies. Med. Care 37(4 Suppl.), A532—A535, (1999).
  • Ortega A, Dranitsaris G, Puodziunas ALV What are cancer patients willing to pay for prophylactic epotin alfa? Cancer83, 2588–2596 (1998).
  • Sacristan JA, Kennedy-Martin T, Rosell R et al. Economic evaluation in a randomized Phase III clinical trial comparing gemcitabine/cisplatin and etoposide/ cisplatin in non-small cell lung cancer. Lung Cancer 28,97–107 (2000).
  • Hillner BE, Agarwala S, Middleton MR. Post hoc economic analysis of temozolomide versus dacarbazine in the treatment of advanced metastatic melanoma. j Clin. OncoL 18,1474–1480 (2000).
  • Hillner BE, Weeks JC, Desch CE, Smith TJ. Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis. j Clin. OncoL 18,72–79 (2000).
  • Noe LL, Becker RV, Gradishar WJ, Gore M, Trotter JP The cost-effectiveness of tamoxifen in the prevention of breast cancer. Am. j Managed Care 5(6 Suppl.), S389—S406 (1999).
  • Forbes C, Shirran L, Bagnall AM, Duffy S, ter Riet G. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer. Health TechnoL Asww. 5(28), 1–110 (2001).
  • Neymark N, Adriaenssen I, Gorlia T, Caleo S, Bolla M, Brochon D. Cost-effectiveness of the addition of early hormonal therapy in locally advanced prostate cancer: results decisively determined by the cut-off time-point chosen for the analysis. Eur. J. Cancer 37,1768–1774 (2001).
  • Gonzalez-Larriba JL, Serrano S, Alvarez- Mon M et al. Cost-effectiveness analysis of interferon as adjuvant therapy in high-risk melanoma patients in Spain. Eur. J. Cancer 36,2344–2352 (2000).
  • Orr JW, Orr P, Kern DH. Cost-effective treatment of women with advanced ovarian cancer by cytoreductive surgery and chemotherapy directed by an in vitro assay for drug resistance. Cancerj Sci. Am. 5, 174–178 (1999).
  • Levy-Piedbois C, Durand-Zaleski I, Juhel H, Schmitt C, Bellanger A, Piedbois P. Cost-effectiveness of second-line treatment with ironotecan or infusional 5-fluorouracil in metastatic colorectal cancer. Ann. OncoL 11, 157–161 (2000).
  • Annemans L, Glaccone G, Vergnenegre A. The cost-effectiveness of paclitaxel (Taxo16) + cisplatin is similar to that of teniposide + cisplatin in advanced non-small lung cancer: a multicountry analysis. Anti Cancer Drugs10, 605–615 (1999).
  • Cellini N, Costamagna G, Morganti AG. Concomitant radiochemotherapy in uresectable carcinoma of the exocrine pancreas: cost-effectiveness analysis. Rays 24(3), 447–452 (1999).
  • Sweetenharn J, Hieke K, Kerrigan M et al. Cost- minimization analysis of CHOP, fludarabine and rituximab for the treatment of relapsed indolent B-cell non-Hodgkins lymphoma in the UK Br: fiaerzzatol 106,47–54 (1999).
  • Earle CC, Evans WK. Cost-effectiveness of paclitaxel plus cisplatin in advanced non-small-cell lung cancer. Br. J. Cancer 80(5/ 6), 815–820 (1999).
  • Berger K, Fischer T, Szucs TD. Cost- effectiveness analysis of paclitaxel and cisplatin versus cyclophosphamide and cisplatin as first-line therapy in advanced ovarian cancer. A European perspective. Eur. I Cancer34(12), 1894–1901 (1998).
  • Wirt DP, Giles FJ, Oken MM, Solal-Celigny P, Beck R. Cost-effectiveness of interferon Alfa-2b added to chemotherapy for high-tumor-burden follicular non-Hodgkin's lymphoma. Leuk. Lymphoma 40(5–6), 565–579 (2001).
  • Orr RK, Col NF, Kuntz KM. A cost- effectiveness analysis of axillary node dissection in postmenopausal women with estrogen receptor-positive breast cancer and clinically negative axillary nodes. Surgery 126,568–576 (1999).
  • Sibler JH, Fridman M, Shpilsky A et al. Modeling the cost-effectiveness of granulocyte colony-stimulating factor use in early-stage breast cancer. J. Clin. OncoL 16,2435–2444 (1998).
  • Li N, Van Agthoven M, Willemse PHB, Uyl-de Groot CA. A cost-utility analysis comparing second-line chemotherapy schemes in patients with metastatic breast cancer. Anti Cancer Drugs 12,533–540 (2001).
  • Sampson FC, Beard SM, Scott F, Vandenberghe E. Cost-effectiveness of high-dose chemotherapy in first-line treatment of advanced multiple myeloma. Br. HaematoL 113,1015–1019 (2001).
  • Dranitsaris G, Leung P, Mather J, Oza A. Cost-utility of second-line hormonal therapy in advanced breast cancer: a comparison of two aromatase inhibitors to megestrol acetate. AntiCancer Drugs 11, 591–601 (2000).
  • Bayoumi AM, Brown AD, Garber AM. Cost-effectiveness of androgen suppression therapies in advanced prostate cancer. J. Natl Cancer Inst. 92,1731–1739 (2000).
  • Durand-Zaleski I, Earlam S, Fordy C, Davies M, Allen-Mersh TG. Cost-effectiveness of systemic and regional chemotherapy for the treatment of patients with unresectable colorectal liver metastases. Cancer83, 882–888 (1998).
  • Hillner BE, Radice D. Cost-effectiveness analysis of exemestane compared with megestrol in patients with advanced breast carcinoma. Cancer 91,484–489 (2001).
  • Dranitsaris G. Pamidronate for the prevention of skelet al-related events in multiple myeloma. What does the public think it is worth? Int. j TechnoL Assess. Healthcare 15(1), 108–122 (1999).
  • Schonfeld WH, Elkin EP, Woltering EA et al. The cost-effectiveness of octreotide acetate in the treatment of carcinoid syndrome and VIPoma. mt. j TechnoL Assess. Healthcare 14 (3), 514–525 (1998).
  • Bennett CL, Golub RM, Stinson TJ et al. Cost-effectiveness analysis comparing liposomal anthracyclines in the treatment of AIDS-related Kaposi's sarcoma. Acq. Immune Defic. Synd Human RetroviroL 18, 460–465 (1998).
  • Ferguson JSJ, Summerhayes M, Masters S, Schey S, Smith IE. New treatment of advanced cancer: an approach to prioritization. Br. Cancer 83 (10), 1268–1273 (2000).
  • Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Critical assessment of economic evaluation. In: Methods for the economic evaluation of healthcare programs (2nd edition). Oxford University Press, Oxford, UK, 27–51 (1997).
  • Basskin LE. How to evaluate the validity and usefulness of pharmacoeconomic literature. In: Practical pharmacoeconomics, How to design, perform and analyze outcomes research. Advanstar Communications, Cleveland, OH, USA 95–101 (1998).
  • Chandramouli JC, Tyler LS. How to evaluate an outcomes study. Hosp. Pharm. 36(2), 131–142 (2001).
  • O'Leary DS. The joint commission looks to the future. JAMA 258,151–152 (1987).
  • Epstein AM. The outcomes movement - will it get us where we want to go? N Engl. Med. 323(4), 266–269 (1990).
  • Ellwood PM. Outcomes management: a technology of patient experiences. N Engl. Med. 318,1549–1556 (1988).
  • Weeks J, Pfister DG. Outcomes research studies. Oncology (Huntington)10 (11 Suppl.), 29–34 (1996).
  • Weeks J. Overview of outcomes research and management and its role in oncology practice. Oncology (Huntington) 12(3 Suppl. 4), 11–13 (1998).

Websites

  • American Cancer Society. Cancer Facts and Figures 2002. www.cancer.org.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.